A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Inclusion Criteria: * Adults \> 18 years of age * Undergone allogeneic HSCT * Written informed consent * Patients with treatment refractory infections with adenovirus, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) will be included in case of fulfilling following criteria: Patient with Adenovirus Infection: 1. Antiviral treatment with cidofovir for at least 7 days * no virus load decrease ( ≤ 1 log) or virus load increase on treatment for at least 7 days or * cluster of differentiation 3 (CD3) + cells \< 300/µL on treatment for at least 7 days 2. Or if antiviral treatment is contraindicated Patient with EBV: 1\. After receipt of at least one anti-cluster of differentiation 20 antigen (CD20)-antibody treat-ment (375 mg/m2) * No Virus load decrease (≤ 1 log) or virus load increase 7 days after receipt of treatment or * CD3+ cells \< 300/µL 7 days after receipt of treatment or * Clinical progression Patient with CMV: 1. Antiviral treatment with ganciclovir or foscavir for 14 days \- No Virus load decrease (≤ 1 log) or virus load increase on day 14 2. Or if \> 2 recurrences despite antiviral treatment with ganciclovir or foscavir for 14 days and CD3+ cells \< 300/µL 3. Or if antiviral treatment is contraindicated - Patient Exclusion Criteria: * graft-versus-host disease (GVHD) \> grade 2 at the time point of planned infusion * Known allergy to iron-dextran or murine antibodies